Lung Cancer Trial, Not Yet Recruiting NCT06757114 Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Not Yet Recruiting

NCT06757114
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People diagnosed with a type of lung cancer called non-small cell lung cancer (which includes subtypes such as adenocarcinoma, squamous cell carcinoma, adenosquamous cell carcinoma, large cell lung cancer, or others), confirmed by laboratory testing of cells or tissue.
  • People with non-small cell lung cancer at any stage who are receiving immunotherapy for the first time.
  • People who have already completed at least 2 rounds (cycles) of immunotherapy and have had at least one check-up to see how the treatment is working.
  • People who have at least one measurable area of cancer that can be tracked using standard medical imaging guidelines (except for people with uncontrolled cancer that has spread to the brain).
  • People who are willing to take part in the study and are happy to cooperate with the research team.
  • People who have lived in Qinghai Province since birth.
  • People who have lived in Shaanxi Province since birth.
  • People who are at least 18 years old.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose lung cancer type cannot be identified through laboratory testing.
  • People whose diagnosis details, treatment history, or records of side effects from immunotherapy are unclear or incomplete.
  • People who have another type of cancer alongside their non-small cell lung cancer (multiple or separate primary cancers).
  • People who are unwilling to participate or are not willing to cooperate with the study.
  • People who moved to Qinghai or Shaanxi from a different altitude, or who have a history of moving between the two provinces.
  • People whose parents have a history of emigrating from another region (confirm with trial site).
  • People who have previously received immunotherapy for a different cancer.
  • People who have previously received treatment that suppresses the immune system (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 8613572824106

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
31 May 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

Efficacy of first-line immunotherapy for advanced non-small cell lung cancer at high and low altitudes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov